Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 2K | 31K | 0 |
| Gross Profit | 0 | 2K | 16K | 0 |
| Operating Income | -51K | -58K | -37K | -43K |
| EBITDA | -51K | -10K | -29K | -43K |
| Net Income | -61K | -25K | -41K | -43K |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$2.49
+0.00% today
1Y Change
-41.41%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Welsis Corp. (WLSS) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $2.49 and down 41.4% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -122.2%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -122.2%, free cash flow -66.6% with operating margin 0.0% and ROIC 42.9%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WLSS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WLSS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WLSS Max Drawdown
-90.58%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WLSS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$42.8K
-4.2% YoY
Free Cash Flow
-$70.1K
-220.6% YoY
Revenue Growth
-100.0%
EPS Growth
-122.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 2K | 31K | 0 |
| Gross Profit | 0 | 2K | 16K | 0 |
| Operating Income | -51K | -58K | -37K | -43K |
| EBITDA | -51K | -10K | -29K | -43K |
| Net Income | -61K | -25K | -41K | -43K |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2023 | 2022 |
|---|---|---|---|
| Cash & Equivalents | 0 | 10K | 0 |
| Total Assets | 2K | 33K | 50K |
| Total Liabilities | 68K | 151K | 127K |
| Shareholder Equity | -150K | -118K | -77K |
| Total Debt | 0 | 80K | 40K |
| Net Debt | 0 | 70K | 40K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
39K
-77.3% YoY
Capital Expenditures
31K
-34.3% YoY
Free Cash Flow
70K
-220.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
32.9%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.